Drug
Treprostinil Smi
Treprostinil Smi: highest development phase Phase 2/3, developed by United Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| treprostinil SMI (treprostinil inhalation spray) NCT07923526 | Phase 2/3 | Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease |
| treprostinil SMI (treprostinil inhalation spray) NCT07923591 | Phase 2 | Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease |
Latest
No recent events.
Follow Treprostinil Smi on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.